Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

CORONADO, Calif. — Despite recent advances in the treatment of cutaneous squamous cell carcinoma (SCC), a lack of consensus ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at AFC Telford's match on Saturday.

People attending a football match will be asked to sign up to a stem cell register in the hope of finding a donor for a local man. Marshall Davies, 21, from Telford, was diagnosed with a rare and ...

Marshall Davies, 21, from Telford, was diagnosed with a rare and potentially aggressive type of cutaneous T-cell lymphoma in April 2023. In December he received the news it had progressed to ...

The microenvironment of Hodgkin's lymphoma is affected by IL-5 which recruits eosinophiles and by TARC/CCL17 which attract CD4+ T-lymphocytes. CCR4, the receptor for TARC, is a target for therapy of ...

Researchers have revolutionized cancer immunotherapy by developing a way to grow T cells in the lab that live longer and fight cancer more effectively. They identified flaws in traditional methods, ...